tiprankstipranks
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Shareholders Back Board, Pay, and Auditor
Company AnnouncementsArcturus Shareholders Back Board, Pay, and Auditor
11d ago
8K
ARCT
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
PremiumCompany Announcements
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
28d ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
PremiumRatings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
28d ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
PremiumRatings
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
1M ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
PremiumCompany Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
1M ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
PremiumRatingsMyles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
1M ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
Premium
Company Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
1M ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
Premium
The Fly
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
1M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
PremiumMarket News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
2M ago
WGS
ARCT
Arcturus Therapeutics initiated with a Buy at B. Riley
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at B. Riley
3M ago
ARCT
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
3M ago
ARCT
Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
PremiumCompany AnnouncementsRegulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
3M ago
ARCT
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
Premium
Company Announcements
Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
3M ago
ARCT
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
Premium
The Fly
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
3M ago
ARCT
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
PremiumRatings
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
3M ago
ARCT
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
PremiumRatings
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
3M ago
ARCT
Arcturus Therapeutics price target raised to $8 from $7 at Citi
PremiumThe Fly
Arcturus Therapeutics price target raised to $8 from $7 at Citi
3M ago
ARCT
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
PremiumThe Fly
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
3M ago
ARCT
Options Volatility and Implied Earnings Moves Today, March 03, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, March 03, 2026
4M ago
AZO
BBY
ARCT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ARCT Earnings this Week: How Will it Perform?
4M ago
ARCT
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
Premium
Company Announcements
Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
5M ago
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >